Journal ArticleOPEN ACCESS

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

  • Chen J
  • Hu X
  • Li Q
  • et al.
Annals of Translational Medicine (2020) 8(18) 1187-1187
DOI: 10.21037/atm-20-6063
N/ACitations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Background: The clinical significance of programmed cell death protein-1 (PD-1)-targeted

Cite

CITATION STYLE

APA

Chen, J., Hu, X., Li, Q., Dai, W., Cheng, X., Huang, W., … Yuan, G. (2020). Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Annals of Translational Medicine, 8(18), 1187–1187. https://doi.org/10.21037/atm-20-6063

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free